73090-70-7|Epiroprim|5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine|-范德生物科技公司

Epiroprim

NMR下载 COA and HPLC MSDS下载
names：
5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine
CAS号：
73090-70-7
MDL Number：
MF(分子式)： C19H23N5O2 MW(分子量)： 353.42
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Epiroprim
英文别名	Epiroprim; Epiroprime; Ro 11-8958; Ro-11-8958; Ro11-8958;
CAS号	73090-70-7
SMILES	CCOC1=C(N2C=CC=C2)C(OCC)=CC(CC3=CN=C(N)N=C3N)=C1
Inchi	InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)
InchiKey	NMARPFMJVCXSAV-UHFFFAOYSA-N
分子式 Formula	C19H23N5O2
分子量 Molecular Weight	353.42
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Epiroprim(CAS:73090-70-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Epiroprim is an analog of trimethoprim and an inhibitor of dihydrofolate reductase.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Martinez A, Allegra CJ, Kovacs JA. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am J Trop Med Hyg. 1996 Mar;54(3):249-52. PubMed PMID: 8600759.

[2]Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999 Aug;12(4):319-23. PubMed PMID: 10493608.

[3] Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803-7. PubMed PMID: 7986011; PubMed Central PMCID: PMC284639.

[4] Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci. 2003 Oct;92(10):1990-2007. PubMed PMID: 14502539.

[5] Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother. 1996 Jun;40(6):1376-81. PubMed PMID: 8726004; PubMed Central PMCID: PMC163334.

6: Lee HS, Chang HR, Khoo YM. Simple HPLC determination of the concentrations of epiroprim in the serum and brains of mice. J Pharm Pharmacol. 1996 Oct;48(10):1090-2. PubMed PMID: 8953514.7: N'guessan K, Dosso M, Marchal G, Chavarot P, Romain F, Pescher P, Edy. [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. Bull Soc Pathol Exot. 2002 Nov;95(4):265-8. French. PubMed PMID: 12596375.8: Dosso M, Ouattara L, Cherif AM, Bouzid SA, Haller L, Fernex M. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis. Chemotherapy. 2001 Mar-Apr;47(2):123-7. PubMed PMID: 11173814.9: Mehlhorn H, Dankert W, Hartman PG, Then RL. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol Res. 1995;81(4):296-301. PubMed PMID: 7624286.10: Brun-Pascaud M, Chau F, Garry L, Jacobus D, Derouin F, Girard PM. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother. 1996 Sep;40(9):2067-70. PubMed PMID: 8878582; PubMed Central PMCID: PMC163474.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开